Current Edition

cancer drugs

Merck, Roche and J&J among pharma players weighing Russian operations amid humanitarian tightrope walk

You can’t buy a Coke, Frappuccino or Big Mac in Russia anymore, but cancer patients may still be able to get Merck’s megablockbuster Keytruda. While …

Continue Reading →
Merck

As Russian invasion persists, Roche, Teva, Novartis, Merck and more make renewed push to support besieged Ukraine

As Ukraine holds the line against the Russian invasion, pharma majors are making a renewed push to adjust operations in the region and supply the …

Continue Reading →
childbirth

Merck, putting $150M on the table, doubles down on pledge to tackle maternal mortality and health inequities

Around the world, a woman dies every two minutes from pregnancy or childbirth complications, most of them preventable. Merck has spent the last decade trying …

Continue Reading →
COVID-19 pill

Buffett’s Berkshire exited Merck investment just before COVID pill boost, further trimmed AbbVie and BMS holdings

Warren Buffett’s Berkshire Hathaway doesn’t appear to be the oracle of every market movement, at least not in the case of an investment in Merck …

Continue Reading →
COVID-19

With Merck’s oral COVID-19 med molnupiravir set for authorization, U.S. spends another $1B for 1.4 million courses

With molnupiravir, Merck & Co. and Ridgeback’s oral treatment for COVID-19, apparently on the doorstep of authorization, the U.S. has moved to secure additional doses …

Continue Reading →
Acceleron Pharma

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators’ review time only one benefit

Merck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has …

Continue Reading →
Ilaris

Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure

Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be …

Continue Reading →
Acceleron

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck’s new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks …

Continue Reading →
antiviral molnupiravir

Merck and Ridgeback’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst

What do Merck and Ridgeback’s eye-opening data, recently released for its antiviral molnupiravir on high-risk COVID-19 patients, mean for manufacturers of vaccines? Analysts from the …

Continue Reading →
children

Racing rival Pfizer, Merck’s Vaxneuvance makes its case for an FDA approval in children

Time is of the essence for Merck as the company races with rival Pfizer to gain an FDA approval for its next-generation pneumococcal vaccine in …

Continue Reading →